FR14C0033I1 - - Google Patents

Info

Publication number
FR14C0033I1
FR14C0033I1 FR14C0033C FR14C0033I1 FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1 FR 14C0033 C FR14C0033 C FR 14C0033C FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0033I1 publication Critical patent/FR14C0033I1/fr
Application granted granted Critical
Publication of FR14C0033I2 publication Critical patent/FR14C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR14C0033C 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine Active FR14C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
FR14C0033I1 true FR14C0033I1 (enrdf_load_stackoverflow) 2014-06-13
FR14C0033I2 FR14C0033I2 (fr) 2014-11-14

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0033C Active FR14C0033I2 (fr) 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine

Country Status (38)

Country Link
US (10) US7144884B2 (enrdf_load_stackoverflow)
EP (2) EP1749818B1 (enrdf_load_stackoverflow)
JP (3) JP3896116B2 (enrdf_load_stackoverflow)
KR (3) KR100842702B1 (enrdf_load_stackoverflow)
CN (1) CN1319958C (enrdf_load_stackoverflow)
AR (2) AR036659A1 (enrdf_load_stackoverflow)
AT (2) ATE441631T1 (enrdf_load_stackoverflow)
AU (2) AU2002333220C1 (enrdf_load_stackoverflow)
BE (1) BE2014C036I2 (enrdf_load_stackoverflow)
BR (3) BRPI0212733B8 (enrdf_load_stackoverflow)
CA (1) CA2462110C (enrdf_load_stackoverflow)
CO (1) CO5580746A2 (enrdf_load_stackoverflow)
CY (3) CY1107924T1 (enrdf_load_stackoverflow)
DE (2) DE60225162T3 (enrdf_load_stackoverflow)
DK (2) DK1436271T6 (enrdf_load_stackoverflow)
EA (2) EA011096B1 (enrdf_load_stackoverflow)
EG (1) EG25095A (enrdf_load_stackoverflow)
ES (2) ES2328725T3 (enrdf_load_stackoverflow)
FR (1) FR14C0033I2 (enrdf_load_stackoverflow)
HR (1) HRP20040220A2 (enrdf_load_stackoverflow)
HU (3) HU230189B1 (enrdf_load_stackoverflow)
IL (1) IL160655A0 (enrdf_load_stackoverflow)
IS (2) IS2578B (enrdf_load_stackoverflow)
LT (1) LTC1436271I2 (enrdf_load_stackoverflow)
LU (1) LU92397I2 (enrdf_load_stackoverflow)
ME (1) ME00039B (enrdf_load_stackoverflow)
MX (1) MXPA04002959A (enrdf_load_stackoverflow)
MY (1) MY140950A (enrdf_load_stackoverflow)
NL (1) NL300652I2 (enrdf_load_stackoverflow)
NO (3) NO326443B1 (enrdf_load_stackoverflow)
NZ (1) NZ531556A (enrdf_load_stackoverflow)
PL (2) PL210551B1 (enrdf_load_stackoverflow)
PT (2) PT1749818E (enrdf_load_stackoverflow)
RS (2) RS52326B (enrdf_load_stackoverflow)
SI (1) SI1436271T1 (enrdf_load_stackoverflow)
UA (2) UA81749C2 (enrdf_load_stackoverflow)
WO (1) WO2003029232A1 (enrdf_load_stackoverflow)
ZA (1) ZA200401583B (enrdf_load_stackoverflow)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
UA81469C2 (en) * 2003-04-04 2008-01-10 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
CL2004000725A1 (es) * 2003-04-04 2005-02-18 Lundbeck & Co As H Compuestos derivados de 4-(2-fenilsulfanilfenil)piperidina; composicion farmaceutica; y uso del compuesto para el tratamiento de trastornos afectivos como la depresion, trastornos de ansiedad, trastorno obsesivo compulsivo, trastorno de panico, ataqu
PT1635828E (pt) * 2003-04-04 2008-07-01 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
DE602004016316D1 (de) * 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
EP1701940B1 (en) 2003-12-23 2008-05-28 H.Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) * 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
PT2044020E (pt) * 2006-06-16 2011-05-12 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfanil)- fenil] piperidina com inibi??o de reabsor??o combinada de serotonina e norepinefrina para o tratamento da dor neurop?tica
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
ZA200809917B (en) * 2006-06-16 2010-08-25 Lundbeck & Co As H Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
KR101656338B1 (ko) 2008-11-14 2016-09-09 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 4­［2­（2­플루오로페녹시메틸）페닐］피페리딘 화합물의 결정형
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
UA106985C2 (uk) 2009-04-24 2014-11-10 Х. Луннбек А/С Рідкі склади солей 1-[2-(2,4-диметилфенілсульфаніл)феніл]піперазину
GEP20135950B (en) 2009-08-24 2013-10-25 H Lundbeck As New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine
EP2493852B1 (en) * 2009-10-30 2014-04-09 Janssen Pharmaceutica NV 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
WO2011136376A1 (ja) 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
KR20130060220A (ko) * 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
RS55304B1 (sr) 2011-06-20 2017-03-31 H Lundbeck As Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
SMT201900248T1 (it) * 2012-01-03 2019-07-11 H Lundbeck As Processo per la produzione di 1-[2-(2,4-dimetil - fenilsolfanil)-fenil]piperazina
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
MY171802A (en) 2012-12-13 2019-10-30 H Lundbeck As Compositions comprising vortioxetine and donepezil
SMT201700238T1 (it) * 2013-02-22 2017-07-18 H Lundbeck As Procedimento per la produzione di vortioxetina
ES2724246T3 (es) 2013-04-04 2019-09-09 Lek Pharmaceuticals Nuevo proceso para la síntesis de 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
US10414741B2 (en) 2013-09-30 2019-09-17 Cadila Healthcare Limited Amorphous vortioxetine and salts thereof
EP2878596A1 (en) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
JP7000321B2 (ja) * 2015-07-17 2022-02-10 アンスティテュ・パストゥール 衛星細胞の自己再生および／または分化の促進剤としての使用のための５－ヒドロキシトリプタミン１ｂ受容体刺激剤
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
EP3478289A1 (en) 2016-07-01 2019-05-08 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
BR112019000706A8 (pt) 2016-07-15 2022-12-06 Pasteur Institut Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
WO2018014880A1 (zh) * 2016-07-22 2018-01-25 李勤耕 沃替西汀类似物及其用途和制备
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (en) * 2017-02-23 2020-08-12 Unichem Laboratories Ltd IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE
WO2018197360A1 (en) * 2017-04-25 2018-11-01 H. Lundbeck A/S Process for the manufacture of vortioxetine hbr alpha-form
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
WO2019242889A1 (en) 2018-06-20 2019-12-26 Vio Ag Pharmaceuticals S.A. A one-pot organo-pseudocatalytic c-h activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151755B1 (enrdf_load_stackoverflow) 1971-04-13 1973-11-19
CS151751B1 (enrdf_load_stackoverflow) 1971-04-13 1973-11-19
CS151752B1 (enrdf_load_stackoverflow) 1971-04-13 1973-11-19
CS151753B1 (enrdf_load_stackoverflow) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) * 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69828317T2 (de) * 1997-10-31 2005-05-25 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von N-((4-Phenyl)methylphenyl)piperazinen
KR20020003559A (ko) 1999-04-02 2002-01-12 게리 엘. 윌콕스 Ｌｆａ-1의 ｉｃａｍ에 대한 결합 저해제 및 그 용도
AU6621600A (en) 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
WO2001049681A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
CZ20022319A3 (cs) * 1999-12-30 2002-10-16 H. Lundbeck A/S Substituovaná fenylpiperazinová sloučenina a farmaceutický prostředek, který ji obsahuje
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
EP1370558B1 (en) * 2001-01-23 2005-08-24 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
HUP0402320A2 (hu) * 2001-12-20 2005-03-29 H. Lundbeck A/S Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
DE602004016316D1 (de) * 2003-04-04 2008-10-16 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity

Also Published As

Publication number Publication date
KR20040047886A (ko) 2004-06-05
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
EA007537B1 (ru) 2006-10-27
CN1561336A (zh) 2005-01-05
LTC1436271I2 (lt) 2016-09-12
AR036659A1 (es) 2004-09-22
RS20120158A2 (en) 2012-10-31
PL210551B1 (pl) 2012-02-29
NL300652I1 (enrdf_load_stackoverflow) 2016-01-18
US20050014740A1 (en) 2005-01-20
JP3955614B2 (ja) 2007-08-08
EG25095A (en) 2011-08-17
NO326443B1 (no) 2008-12-08
US20110009423A1 (en) 2011-01-13
EA011096B1 (ru) 2008-12-30
EA007537B3 (ru) 2015-02-27
ATE386730T1 (de) 2008-03-15
CY1110064T1 (el) 2015-01-14
BR122012023120B8 (pt) 2022-01-18
AR066460A2 (es) 2009-08-19
NO20083446L (no) 2004-04-21
JP3896116B2 (ja) 2007-03-22
DK1436271T6 (da) 2022-06-27
BRPI0212733B8 (pt) 2021-05-25
US7138407B2 (en) 2006-11-21
DE60225162D1 (de) 2008-04-03
CA2462110C (en) 2010-05-11
IS8806A (is) 2009-03-10
AU2002333220A2 (en) 2003-04-14
ZA200401583B (en) 2005-05-25
PT1436271E (pt) 2008-04-10
IS2578B (is) 2010-02-15
HUS1400012I1 (hu) 2020-12-28
US7683053B2 (en) 2010-03-23
CN1319958C (zh) 2007-06-06
CO5580746A2 (es) 2005-11-30
CY1107924T1 (el) 2013-09-04
KR20070103515A (ko) 2007-10-23
AU2006215994A2 (en) 2006-10-05
US20140163043A1 (en) 2014-06-12
EP1749818A3 (en) 2008-04-02
AU2002333220B2 (en) 2008-02-07
NO332355B1 (no) 2012-09-03
KR100842702B1 (ko) 2008-07-01
IS2732B (is) 2011-04-15
US20180127389A1 (en) 2018-05-10
US20070060574A1 (en) 2007-03-15
BR122012023120B1 (pt) 2017-03-21
CA2462110A1 (en) 2003-04-10
MY140950A (en) 2010-02-12
US10844029B2 (en) 2020-11-24
NO2014011I2 (no) 2015-08-31
EA200601269A1 (ru) 2007-02-27
RS20120158A3 (en) 2013-10-31
CY2014022I2 (el) 2015-12-09
HRP20040220A2 (en) 2005-02-28
IS7164A (is) 2004-02-26
SI1436271T1 (sl) 2008-06-30
BR122012009534C8 (pt) 2021-05-25
US20060089368A1 (en) 2006-04-27
MEP6508A (xx) 2010-02-10
AU2006215994B2 (en) 2008-11-13
ES2298425T7 (es) 2022-06-27
HU228956B1 (en) 2013-07-29
NO20041628L (no) 2004-04-21
JP2005505585A (ja) 2005-02-24
IL160655A0 (en) 2004-07-25
BR122012009534B8 (pt) 2019-01-29
EA200400498A1 (ru) 2004-08-26
BE2014C036I2 (enrdf_load_stackoverflow) 2021-11-22
US7144884B2 (en) 2006-12-05
EP1436271B3 (en) 2022-04-20
UA93857C2 (uk) 2011-03-25
US20120302553A1 (en) 2012-11-29
EP1436271B1 (en) 2008-02-20
NO2014011I1 (no) 2014-05-13
BR0212733B1 (pt) 2014-05-13
DE60225162T3 (de) 2022-08-11
HUP0402313A2 (hu) 2005-02-28
WO2003029232A1 (en) 2003-04-10
DK1749818T3 (da) 2009-10-12
DE60233608D1 (de) 2009-10-15
BR122012009534B1 (pt) 2018-02-27
JP3955613B2 (ja) 2007-08-08
EP1749818B1 (en) 2009-09-02
DK1436271T3 (da) 2008-06-09
AU2006215994A1 (en) 2006-10-05
FR14C0033I2 (fr) 2014-11-14
EP1436271A1 (en) 2004-07-14
ES2298425T3 (es) 2008-05-16
ATE441631T1 (de) 2009-09-15
EP1749818A2 (en) 2007-02-07
ME00039B (me) 2010-06-10
PT1749818E (pt) 2009-10-06
US20060084662A1 (en) 2006-04-20
PL368442A1 (pl) 2005-03-21
US7148238B2 (en) 2006-12-12
MXPA04002959A (es) 2004-07-05
BR0212733A (pt) 2004-11-16
US20210276966A1 (en) 2021-09-09
NL300652I2 (enrdf_load_stackoverflow) 2016-01-18
HUP0402313A3 (en) 2010-03-29
KR20060118020A (ko) 2006-11-17
DE60225162T2 (de) 2009-02-12
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
CA2462110E (en) 2003-04-10
US8476279B2 (en) 2013-07-02
US9708280B2 (en) 2017-07-18
HU230189B1 (hu) 2015-09-28
KR100783346B1 (ko) 2007-12-07
HK1072600A1 (en) 2005-09-02
CY2014022I1 (el) 2015-12-09
RS27704A (en) 2006-10-27
KR100770194B1 (ko) 2007-10-25
UA81749C2 (uk) 2008-02-11
JP2007051149A (ja) 2007-03-01
US9090575B2 (en) 2015-07-28
AU2002333220C1 (en) 2023-10-05
JP2007031447A (ja) 2007-02-08
US20160137620A1 (en) 2016-05-19
AU2006215994A9 (en) 2006-10-05
PL209253B1 (pl) 2011-08-31
ES2328725T3 (es) 2009-11-17
RS52865B (en) 2013-12-31

Similar Documents

Publication Publication Date Title
BE2022C531I2 (enrdf_load_stackoverflow)
BE2022C547I2 (enrdf_load_stackoverflow)
BE2017C059I2 (enrdf_load_stackoverflow)
BE2017C055I2 (enrdf_load_stackoverflow)
BE2017C051I2 (enrdf_load_stackoverflow)
BE2017C032I2 (enrdf_load_stackoverflow)
BE2016C051I2 (enrdf_load_stackoverflow)
FR14C0033I1 (enrdf_load_stackoverflow)
BE2017C050I2 (enrdf_load_stackoverflow)
BE2012C050I2 (enrdf_load_stackoverflow)
BE2014C006I2 (enrdf_load_stackoverflow)
JP2002222957A5 (enrdf_load_stackoverflow)
BRPI0209186B1 (enrdf_load_stackoverflow)
BRPI0204884A2 (enrdf_load_stackoverflow)
CH1379220H1 (enrdf_load_stackoverflow)
HU0202285D0 (enrdf_load_stackoverflow)
BE2014C008I2 (enrdf_load_stackoverflow)
BRPI0101486B8 (enrdf_load_stackoverflow)
JP2002240658A5 (enrdf_load_stackoverflow)
BE2012C051I2 (enrdf_load_stackoverflow)
JP2002243428A5 (enrdf_load_stackoverflow)
JP2002202879A5 (enrdf_load_stackoverflow)
JP2002235437A5 (enrdf_load_stackoverflow)
BRPI0210463A2 (enrdf_load_stackoverflow)
JP2002231855A5 (enrdf_load_stackoverflow)